Top 25 Companies in Global Liraglutide Injection Market (2025–2035): Expert View by Spherical Insights

Description

According to a research report published by Spherical Insights & Consulting, The Global Liraglutide Injection Market Size is projected to grow from USD 9.28 Billion in 2025 to USD 26.98 Billion by 2035, at a CAGR of 11.26% during the forecast period 2025–2035. The global liraglutide injection market grows because Type 2 Diabetes and obesity rates increase, people learn about effective treatment options, healthcare spending rises, and injectable drug delivery system technology improves, and GLP-1 receptor agonist therapies become more common in various countries.

 

Introduction

The global liraglutide injection market refers to the pharmaceutical segment focused on injectable therapies used for the treatment of Type 2 Diabetes and obesity. Liraglutide acts as a GLP-1 receptor agonist which enables it to control blood glucose levels while producing insulin and decreasing hunger and assisting with weight loss. The product is available in various markets under its brand names Victoza and Saxenda. The market expansion occurs because three factors drive this trend which are increasing global diabetes and obesity rates and rising public awareness about contemporary treatment methods and growing healthcare expenditures. Patients prefer injectable drug delivery systems which doctors recommend for GLP-1 treatments, so this system has gained acceptance. The demand for products has increased because clinical studies prove their ability to improve heart health and decrease body weight. The global market continues to expand because large pharmaceutical companies conduct research on new combination therapies across various countries. The market expansion receives support from beneficial regulatory approvals and reimbursement programs which exist in developed markets. The implementation of new drug delivery technologies, which includes prefilled pens and easy-to-use injection devices, is increasing patient adherence while providing greater convenience. The growing interest in personalized medicine together with chronic disease management programs is increasing demand for liraglutide-based treatments.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Liraglutide Injection Market.

 

Market Segmentation

Global Liraglutide injection  Market Size, Share, By Strength (6 mg/mL, 18 mg/3 mL, 18 mg/1.5 mL, Other Concentrations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics), By Application (Type 2 Diabetes Mellitus, Obesity Management, Cardiovascular Risk Reduction, Polycystic Ovary Syndrome [PCOS]), By End User (Hospitals, Homecare Settings, Specialty Diabetes Clinics, Weight Management Centers), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035

 

Liraglutide Injection Market Size & Statistics

• The Market Size for Liraglutide injection Was Estimated to be worth USD 9.28 Billion in 2025.
• The Market is Going to Expand at a CAGR of 11.26% between 2025 and 2035.
• The Global Liraglutide Injection Market Size is anticipated to reach USD 26.98 Billion by 2035.
• North America is expected to generate the highest revenue during the forecast period in the Liraglutide Injection Market
• Asia Pacific is expected to grow at the fastest rate during the forecast period in the Liraglutide Injection Market.

 

Regional growth and demand                

Asia Pacific is expected to grow at the fastest rate during the forecast period in the liraglutide injection market. The region experiences growth because more people develop Type 2 Diabetes and obesity, together with rising healthcare costs and better availability of advanced medical treatments. The market growth receives support from two factors: people becoming more aware of weight management treatments and the development of healthcare facilities throughout China and India. The region experiences growing demand because people increasingly use injectable treatments while healthcare providers prioritize early disease detection.

 

North America is expected to generate the highest revenue during the forecast period in the liraglutide injection market. The region's dominant position results from both its extensive healthcare expenditures, its numerous top pharmaceutical companies and its broad adoption of Liraglutide and other modern medical treatments. The region shows strong demand because people now understand obesity management better and because reimbursement policies in the area have become more favorable.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Liraglutide Injection Market.

 

 

Top 10 Trends in the Liraglutide Injection Market

• Rising Prevalence of Type 2 Diabetes and Obesity
• Increasing Adoption of GLP-1 Receptor Agonists
• Growing Demand for Weight Management Therapies
• Advancements in Injectable Drug Delivery Systems
• Strong Clinical Evidence Supporting Cardiovascular Benefits
• Expansion of Indications Beyond Diabetes (Obesity & Metabolic Disorders)
• Rising Healthcare Expenditure in Emerging Economies
• Increasing Focus on Personalized and Precision Medicine
• Strategic Collaborations and R&D Investments by Pharmaceutical Companies
• Development of Next-Generation GLP-1 and Combination Therapies  

 

1. Rising Prevalence of Type 2 Diabetes and Obesity

Global demand for liraglutide injections has expanded because of the rising worldwide incidence of Type 2 diabetes and obesity. The world witnesses a rapidly increasing number of metabolic disorders because people live sedentary lifestyles and consume unhealthy foods, while the population ages. The need for effective Liraglutide treatments has increased because these conditions demand ongoing treatment. The market expansion receives additional support from the government and healthcare organizations which prioritize early diagnosis and treatment. Emerging economies experience strong market growth because their diabetes and obesity rates are rising quickly, which creates major business opportunities for pharmaceutical companies.

 

2. Increasing Adoption of GLP-1 Receptor Agonists

The use of GLP-1 receptor agonists, including Liraglutide, has become common because these drugs effectively manage blood glucose levels while helping people lose weight. The metabolic disorder treatments use hormone-mimicking therapies that control insulin release and appetite, which makes them particularly useful for treating metabolic disorders. Physicians are increasingly prescribing GLP-1 drugs as they offer dual benefits for diabetes and obesity management. The adoption of the technology has grown because it improves patient outcomes while decreasing the chances of developing complications. Pharmaceutical companies are also promoting these therapies through awareness programs and clinical studies, which helps them establish a stronger presence in the worldwide market.

 

3. Growing Demand for Weight Management Therapies

The growing public understanding of obesity-related health dangers drives people to seek weight management solutions that include liraglutide injections. Saxenda serves as a weight loss medication that enables users to lose weight by controlling their food consumption and decreasing their hunger. Effective weight management has become a major healthcare demand because obesity leads to diabetes, cardiovascular diseases and hypertension. The market experiences expansion because consumers show greater interest in fitness and preventive healthcare solutions. Liraglutide has become a major treatment option for weight management because healthcare providers use it as part of their complete treatment plans.

 

4. Advancements in Injectable Drug Delivery Systems

The liraglutide injection market benefits from technological progress, which helps patients receive easier treatments that result in better results. Modern injection devices are designed to be user-friendly, with features such as pre-filled pens, dose accuracy, and minimal discomfort. The new treatment methods help patients to follow their medical plans better because they need to take medications for extended periods. Pharmaceutical companies are continuously investing in research to develop more efficient and convenient delivery systems. The improved packaging and portable design of liraglutide injections, together with their simple usage, enable more patients to access the product, which leads to greater adoption rates and supports market expansion.

 

5. Strong Clinical Evidence Supporting Cardiovascular Benefits

Clinical studies have demonstrated that Liraglutide not only helps manage blood sugar levels but also provides cardiovascular benefits. The medication demonstrates its effectiveness by decreasing major cardiovascular event rates among type 2 diabetes patients. The combination of these two advantages has resulted in a higher acceptance rate from medical professionals and patients. Diabetes medications that also treat heart health conditions have become essential because cardiovascular diseases rank as the primary cause of death across the globe. The ongoing clinical research demonstrates these benefits, which enhance liraglutide's market position while promoting its broad usage.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the liraglutide injection market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Liraglutide Injection Market.

 

Top 25 Companies Leading the Liraglutide Injection Market

1. Novo Nordisk A/S
2. Eli Lilly and Company
3. Sanofi S.A.
4. AstraZeneca plc
5. Pfizer Inc.
6. Merck & Co., Inc.
7. Johnson & Johnson
8. Boehringer Ingelheim GmbH
9. GlaxoSmithKline plc
10. Novartis AG
11. Bristol-Myers Squibb Company
12. Takeda Pharmaceutical Company Limited
13. Teva Pharmaceutical Industries Ltd.
14. Sun Pharmaceutical Industries Ltd.
15. Dr Reddy’s Laboratories Ltd.
16. Cipla Limited
17. Aurobindo Pharma Limited
18. Lupin Limited
19. Biocon Limited
20. Amgen Inc.
21. AbbVie Inc.
22. Regeneron Pharmaceuticals, Inc.
23. Alnylam Pharmaceuticals, Inc.
24. Hikma Pharmaceuticals PLC
25. Zydus Lifesciences Limited

 

1. Novo Nordisk A/S

Headquarters: Bagsvaerd, Denmark

Novo Nordisk A/S is the leading player in the liraglutide injection market and the original developer of Liraglutide. The company markets liraglutide under well-known brands such as Victoza and Saxenda. The company provides cutting-edge injectable products that enable users to treat their Type 2 Diabetes and obesity conditions. The company maintains its leadership through strong research and development capabilities, a global distribution network, and continuous clinical advancements. Novo Nordisk is developing new GLP-1 therapies while expanding its operations in emerging markets, which will enhance its market position and contribute to worldwide market expansion.

 

2. Eli Lilly and Company

Headquarters: Indianapolis, Indiana, USA

Eli Lilly and Company stands as a major player within the diabetes and obesity therapeutics market. The company develops its own GLP-1 products, but Liraglutide remains its secondary product according to market demand. Eli Lilly focuses on developing advanced treatments for metabolic disorders with improved efficacy and better patient outcomes. The company maintains its competitive edge through multiple factors, which include its extensive product development pipeline, worldwide operations and dedication to scientific research. The company establishes competitive advantages through its combination of digital health solutions and patient-centred methods, which create accessible, advanced medical treatments for patients worldwide.

 

3. Sanofi S.A.

Headquarters: Paris, France

Sanofi S.A. is a major force in the worldwide diabetes treatment industry because it provides various insulin and injectable medicine options. The company develops new medical solutions that treat metabolic diseases, which include Type 2 Diabetes and obesity. Sanofi invests heavily in research collaborations and advanced drug development to enhance treatment effectiveness and patient outcomes. The company establishes its global presence through its extensive distribution system, which enables customers in both developed and developing countries to access its products. The company uses its two main functions, which are patient support programs and digital health initiatives, to enhance disease management for its customers. Through its dedication to innovation and its creation of strategic partnerships, Sanofi contributes to the development of liraglutide injection and the GLP-1 therapeutics market.

 

4. AstraZeneca plc

Headquarters: Cambridge, United Kingdom

AstraZeneca plc is a major competitor in markets that treat cardiovascular and metabolic diseases. The company develops treatments that target Type 2 Diabetes and its associated complications, which form part of the larger GLP-1 therapeutic market. AstraZeneca advances patient care through its research work, which creates new medical solutions and its dedication to precision medicine and scientific studies. The company's ability to develop new drugs depends on its international operations and its partnerships with research organisations. The company dedicates major financial resources to developing advanced treatment methods and digital health technologies, which help doctors manage patient diseases more effectively. AstraZeneca contributes to global metabolic disorder treatment development through its dedication to chronic disease research.

 

5. Pfizer Inc.

Headquarters: New York, USA

Pfizer Inc. operates as a major international pharmaceutical firm that develops various groundbreaking medical treatments. Pfizer plays a role in the development of Liraglutide through its work on specialized metabolic and heart disease solutions. The company uses its research activities to develop new medicines and create advanced biologic products, which it combines with industrial partnerships to grow its business. The company uses its extensive international framework and its major investment in clinical research to develop new treatments for chronic illnesses, which include Type 2 Diabetes and obesity. Pfizer develops its competitive advantages through digital health solutions and patient-centered innovations, which help the company succeed in international therapeutic market growth.

 

Are you ready to discover more about the liraglutide injection market?

The report provides an in-depth analysis of the leading companies operating in the global liraglutide injection market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Liraglutide Injection Market.

 

Company Profiles

1. Novo Nordisk A/S

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

1. Eli Lilly and Company
2. Sanofi S.A.
3. AstraZeneca plc
4. Pfizer Inc.
5. Merck & Co., Inc.
6. Johnson & Johnson
7. Boehringer Ingelheim GmbH
8. GlaxoSmithKline plc
9. Others.

 

Our Reports

https://www.sphericalinsights.com/reports/europe-anti-aging-supplements-market
https://www.sphericalinsights.com/reports/europe-ophthalmic-drugs-market
https://www.sphericalinsights.com/reports/europe-methanol-market
https://www.sphericalinsights.com/reports/germany-asphalt-pavers-market
https://www.sphericalinsights.com/reports/france-fertility-services-market

 

Conclusion

The global liraglutide injection market shows consistent expansion because Type 2 Diabetes and obesity rates increase while people learn about new treatment methods, and worldwide healthcare funding grows. Liraglutide serves as a common treatment option that helps patients achieve better blood glucose control while managing their body weight. The treatment provides strong medical advantages through GLP-1 receptor activation, which enables the patient to experience decreased hunger and better control of their insulin production. The market gains additional strength through successful clinical results, which lead to more people using injectable treatments and ongoing research about treating metabolic disorders. Pharmaceutical companies invest their resources into developing innovative products while they construct advanced drug delivery systems and implement market growth strategies. The liraglutide injection market functions as a vital element that helps the world tackle its diabetes and obesity problems.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter